Real-world efficacy of lenvatinib/pembrolizumab combination in anaplastic thyroid carcinoma: case series from two Italian referral centers

Objective: Anaplastic thyroid carcinoma (ATC) is an extremely aggressive cancer, traditionally refractory to conventional treatments. The combined therapy with lenvatinib and pembrolizumab (L + P) is supported by a preclinical rationale based on the distinctive immunological profile of ATC. We propo...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Edoardo Talpacci, Manuela Macera, Giulia Maida, Silvia Morelli, Vincenzo Leone, Chiara Ingriccini, Antonella Ferrieri, Rachele Tortoriello, Miriam Paci, Monia Baldoni, Olivia Morelli, Samuele Barp, Marialuisa Sponziello, Marianna Maranghi, Cosimo Durante, Giorgio Grani, Efisio Puxeddu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Bioscientifica 2026-05-01
Edice:	European Thyroid Journal
Témata:	anaplastic thyroid carcinoma lenvatinib pembrolizumab combination treatment
On-line přístup:	https://etj.bioscientifica.com/view/journals/etj/15/3/ETJ-25-0301.xml
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!